Table 1 Basic characteristics of the studies included in this meta-analysis
Study | Regimen | PN | Area | TP | TG | Patient |
|---|---|---|---|---|---|---|
Bang Y. J 2010 [7] | Trastuzumab + fluoropyrimidine + cisplatin | 294 | worldwide | FL | EGFR | Selected |
fluoropyrimidine-cisplatin | 290 | |||||
Wilke H 2014 [8] | Ramucirumab + paclitaxel | 330 | Asia | SL | VEGFR | Unselected |
Placebo + paclitaxel | 335 | |||||
Shen L 2015 [9] | Bevacizumab + Cisplatin + Capecitabine | 100 | Asia | FL | VEGFR | Unselected |
Placebo + Cisplatin + Capecitabine | 102 | |||||
Lordick F 2013 [10] | Cetuximab + Capecitabine + cisplatin | 455 | worldwide | FL | EGFR | Unselected |
Capecitabine + cisplatin | 449 | |||||
Waddell T 2013 [12] | Panitumumab + mEOC | 278 | Europe | FL | EGFR | Unselected |
Epirubicin + Capecitabine + oxaliplatin | 275 | |||||
Rao S 2010 [13] | matuzumab + Epirubicin + Capecitabine + cisplatin | 35 | Europe | FL | EGFR | Selected |
Epirubicin + Capecitabine + cisplatin | 36 | |||||
NCT01246960 [15] | Ramucirumab + Oxaliplatin + Leucovorin + 5-Fu | 84 | N | FL | VEGFR | Unselected |
Placebo + Oxaliplatin + Leucovorin + 5-Fu | 84 | |||||
Ohtsu A 2011 [16] | Bevacizumab + fluoropyrimidine + cisplatin | 387 | worldwide | FL | VEGFR | Unselected |
Placebo + fluoropyrimidine-cisplatin | 387 | |||||
Du F 2015 [17] | Nimotuzumab + S-1 + Cisplatin | 31 | Asia | FL | EGFR | Unselected |
S-1 + Cisplatin | 31 | |||||
Koizumi W 2013 [18] | TSU-68 + S-1 + cisplatin | 45 | Asia | FL | VEGFR | Unselected |
S-1 + cisplatin | 46 | |||||
Satoh T 2015 [19] | Nimotuzumab + irinotecan | 40 | Asia | SL | EGFR | Unselected |
Irinotecan | 42 | |||||
Satoh T 2014 [20] | lapatinib + paclitaxel | 132 | Asia | SL | EGFR | Selected |
Paclitaxe | 129 | |||||
Yi J. H 2012 [21] | Sunitinib + docetaxel | 56 | Asia | SL | VEGFR | Unselected |
Docetaxel | 49 | |||||
Hecht J. R 2016 [22] | Lapatinib + Capecitabine + Oxaliplatin | 272 | worldwide | FL | EGFR | Selected |
Placebo + Capecitabine + Oxaliplatin | 273 |